All Precision Medicine articles – Page 3
-
NewsNew Lumos AI platform targets precision in mental health drugs
Headlamp Health has launched Lumos AI®, a new decision-support platform designed to bring greater precision to neuroscience drug development.
-
NewsPolysaccharide microneedles: the future of cancer immunotherapy
Polysaccharide-based microneedles are emerging as a dual-action platform for cancer immunotherapy, delivering anti-cancer drugs directly to the skin while actively modulating the immune system.
-
NewsNew AI model links genetic mutations to specific diseases
Scientists have developed a new artificial intelligence tool that can identify harmful genetic mutations and predict the types of diseases they are likely to cause, offering faster diagnosis and new opportunities for drug discovery.
-
ArticleThe future of obesity drugs starts in preclinical discovery
Progress in preclinical models and biomarker science is improving early-stage obesity drug development. This article outlines the emerging targets and technologies behind this shift.
-
NewsNew Spheromatrix platform speeds up cancer drug research
Researchers at NYU Abu Dhabi have developed a cheap, paper-based platform that allows tumour models to be grown, frozen and stored for future cancer drug testing – called Spheromatrix.
-
NewsLive-cell liquid biopsy study aims to transform cancer treatment
Vortex Liquid Biopsy Solutions has launched a new clinical study with The Doctors Laboratory to assess how its live-cell liquid biopsy technology could change cancer monitoring and treatment.
-
NewsMYC inhibitor Omomyc boosts PARP drug response in breast cancer
A preclinical study led by VHIO reveals that the MYC inhibitor Omomyc enhances the effectiveness of PARP inhibitors, offering a potential new treatment strategy for patients with drug-resistant triple-negative breast cancer.
-
ArticleThe partnership changing the pace of radiopharmaceutical development
A new collaboration between Crown Bioscience and Medicines Discovery Catapult is bringing advanced tumour models together with world-class imaging and radiochemistry to accelerate the development of next-generation radiopharmaceuticals.
-
ArticleThe mother of invention: from steam engines to AI-designed drugs
Every great leap in history started with a single, urgent need. Now AI is emerging as the next great engine of invention, transforming the future of medicine faster than ever imagined.
-
ArticleMapping the genome in 3D to reveal new drug targets
Find out how a three-dimensional view of the genome is giving scientists a clearer picture of disease biology and revealing new opportunities for targeted therapies.
-
ArticleMapping lipid pockets to drug the undruggable proteome
Tasca Therapeutics is using chemical proteomics to map lipid-binding pockets on proteins. By targeting auto-palmitoylation, the company aims to turn previously undruggable cancer drivers into viable therapeutic targets.
-
NewsRecycled nuclear fuel to power new cancer treatments in the UK
The UK is set to turn recycled nuclear fuel into new cancer treatments, thanks to a £18.8 million investment in a project using lead-212 to develop Targeted Alpha Therapies.
-
NewsPDX models: a new tool for colorectal cancer research
Patient-derived xenograft models are reshaping colorectal cancer research by preserving the complexity of real tumours, potentially helping scientists to develop new therapies in the future.
-
NewsCRISPR disruption of NRF2 re-sensitises tumours to chemo
Researchers have shown that using CRISPR to disable the NRF2 gene can restore chemotherapy sensitivity and slow tumour growth.
-
ArticleAI and the future of biomarker analysis in early R&D
AI is transforming biomarker analysis in early drug discovery, revealing hidden biological patterns that improve target discovery, patient selection and trial design for more precise and predictive R&D.
-
NewsZuckerberg's Biohub announces AI-powered biology to accelerate drug discovery
The initiative combines cutting-edge artificial intelligence with large-scale biological data, with the aim to transform how new treatments, drugs and therapies are developed.
-
ArticleWhat’s changing in cancer drug discovery – and why it matters now
Take part in a live Q&A with oncology experts as they explore the scientific advances driving cancer drug discovery.
-
ArticleBuilding reliable organoid models for human-relevant drug discovery
Organoids are changing the landscape of biomedical research, with automation and AI driving new levels of consistency, scalability and human relevance. Aaron Risinger of Molecular Devices discusses how these technologies are advancing precision medicine – and the challenges that remain.
-
NewsStem cell liver model reproduces rare immune drug reactions
A new human liver organoid platform could help predict which drugs trigger dangerous immune reactions in susceptible patients.
-
NewsMeta-Flux expands AI platform to speed up drug development
Dublin-based biotech Meta-Flux has raised €1.8M ($2M) in seed funding to expand its AI-driven platform for preclinical drug development, helping researchers predict drug success and accelerate the pathway from lab to clinic.